Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study.

Competing Interests: Declaration of competing interest BPP: grant/research support from Baxalta, Biogen Idec/Sobi, CSL Behring, Novartis, Novo Nordisk, Octapharma, honoraria from Biogen Idec, CSL Behring, LFB, Novo Nordisk, Roche and Takeda, travel support from CSL Behring, Novartis, Novo Nordisk and Sobi; AN received honoraria for speaking from CSL Behring, Bayer, Takeda, Chugai and Sanofi and received research grants from Bayer and Takeda; FAK: nothing to declare; AT: received honoraria for speaking from Bayer, Novo-Nordisk, Werfen, Stago; MTAR: received honoraria for speaking from CSL Behring, Bayer, Takeda, Roche, Novo Nordisk, Sobi, Amgen and Novo Nordisk. WS and YL are employees of CSL Behring; CN: grant/research support from Alnylam, Baxalta, Biogen Idec/Sobi, CSL Behring, Novo Nordisk, Octapharma and Pfizer, honoraria from Biogen Idec, Bayer, CSL Behring, LFB, Novo Nordisk, Pfizer, Roche and Takeda, travel support from CSL Behring, Novo Nordisk and Sobi